Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease

10.1186/1750-1172-9-75

Saved in:

Bibliographic Details
Main Authors:	Kanters, T.A, Hoogenboom-Plug, I, Rutten-Van Mölken, M.P, Redekop, W.K, Van Der Ploeg, A.T, Hakkaart, L
Other Authors:	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
Format:	Article
Published:	2020
Subjects:	recombinant glucan 1,4 alpha glucosidase alpha glucosidase GAA protein, human adolescent adult article child cost effectiveness analysis enzyme replacement female glycogen storage disease type 2 health care cost health care utilization hospital cost human life expectancy major clinical study male middle aged preschool child quality adjusted life year quality of life school child survival teaching young adult cost benefit analysis drug cost economics Glycogen Storage Disease Type II infant newborn pathophysiology alpha-Glucosidases Cost-Benefit Analysis Drug Costs Enzyme Replacement Therapy Humans Infant Infant, Newborn Patient Simulation Quality of Life
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181757
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181757
record_format	dspace
spelling	sg-nus-scholar.10635-1817572023-11-01T07:45:44Z Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease Kanters, T.A Hoogenboom-Plug, I Rutten-Van Mölken, M.P Redekop, W.K Van Der Ploeg, A.T Hakkaart, L SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH recombinant glucan 1,4 alpha glucosidase alpha glucosidase GAA protein, human adolescent adult article child cost effectiveness analysis enzyme replacement female glycogen storage disease type 2 health care cost health care utilization hospital cost human life expectancy major clinical study male middle aged preschool child quality adjusted life year quality of life school child survival teaching young adult cost benefit analysis drug cost economics Glycogen Storage Disease Type II infant newborn pathophysiology alpha-Glucosidases Cost-Benefit Analysis Drug Costs Enzyme Replacement Therapy Glycogen Storage Disease Type II Humans Infant Infant, Newborn Patient Simulation Quality of Life 10.1186/1750-1172-9-75 Orphanet Journal of Rare Diseases 9 1 75 2020-10-28T07:04:51Z 2020-10-28T07:04:51Z 2014 Article Kanters, T.A, Hoogenboom-Plug, I, Rutten-Van Mölken, M.P, Redekop, W.K, Van Der Ploeg, A.T, Hakkaart, L (2014). Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet Journal of Rare Diseases 9 (1) : 75. ScholarBank@NUS Repository. https://doi.org/10.1186/1750-1172-9-75 17501172 https://scholarbank.nus.edu.sg/handle/10635/181757 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	recombinant glucan 1,4 alpha glucosidase alpha glucosidase GAA protein, human adolescent adult article child cost effectiveness analysis enzyme replacement female glycogen storage disease type 2 health care cost health care utilization hospital cost human life expectancy major clinical study male middle aged preschool child quality adjusted life year quality of life school child survival teaching young adult cost benefit analysis drug cost economics Glycogen Storage Disease Type II infant newborn pathophysiology alpha-Glucosidases Cost-Benefit Analysis Drug Costs Enzyme Replacement Therapy Glycogen Storage Disease Type II Humans Infant Infant, Newborn Patient Simulation Quality of Life
spellingShingle	recombinant glucan 1,4 alpha glucosidase alpha glucosidase GAA protein, human adolescent adult article child cost effectiveness analysis enzyme replacement female glycogen storage disease type 2 health care cost health care utilization hospital cost human life expectancy major clinical study male middle aged preschool child quality adjusted life year quality of life school child survival teaching young adult cost benefit analysis drug cost economics Glycogen Storage Disease Type II infant newborn pathophysiology alpha-Glucosidases Cost-Benefit Analysis Drug Costs Enzyme Replacement Therapy Glycogen Storage Disease Type II Humans Infant Infant, Newborn Patient Simulation Quality of Life Kanters, T.A Hoogenboom-Plug, I Rutten-Van Mölken, M.P Redekop, W.K Van Der Ploeg, A.T Hakkaart, L Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
description	10.1186/1750-1172-9-75
author2	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
author_facet	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH Kanters, T.A Hoogenboom-Plug, I Rutten-Van Mölken, M.P Redekop, W.K Van Der Ploeg, A.T Hakkaart, L
format	Article
author	Kanters, T.A Hoogenboom-Plug, I Rutten-Van Mölken, M.P Redekop, W.K Van Der Ploeg, A.T Hakkaart, L
author_sort	Kanters, T.A
title	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
title_short	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
title_full	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
title_fullStr	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
title_full_unstemmed	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
title_sort	cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with pompe disease
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181757
_version_	1781792578975301632

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease

Similar Items